1 Department of Internal
Medicine, 2 Division of Research
and Education and 4 Medical
Physiology and 6 Department of
Psychiatry and Behavioral Science, Bile duct damage
and/or loss is limited to a range of duct sizes in cholangiopathies. We
tested the hypothesis that CCl4
damages only large ducts. CCl4 or
mineral oil was given to bile duct-ligated (BDL) rats, and 1, 2, and 7 days later small and large cholangiocytes were purified and evaluated
for apoptosis, proliferation, and secretion. In situ, we measured
apoptosis by morphometric and TUNEL analysis and the number of small
and large ducts by morphometry. Two days after
CCl4 administration, we found an
increased number of small ducts and reduced number of large ducts. In
vitro apoptosis was observed only in large cholangiocytes, and this was
accompanied by loss of proliferation and secretion in large
cholangiocytes and loss of choleretic effect of secretin. Small
cholangiocytes de novo express the secretin receptor gene and
secretin-induced cAMP response. Consistent with damage of large ducts,
we detected cytochrome P-4502E1 (which
CCl4 converts to its radicals)
only in large cholangiocytes. CCl4
induces selective apoptosis of large ducts associated with loss of
large cholangiocyte proliferation and secretion.
intrahepatic biliary tree; morphometry; proliferation; secretin
receptor; adenosine 3',5'-cyclic monophosphate; bile
secretion
INTRAHEPATIC BILE DUCT epithelial cells or
cholangiocytes form the intrahepatic biliary tree, a ramified network
of interconnecting conduits of different sizes and functions within the
liver (1, 3, 7-8, 10). Cholangiocytes play an important role in
the secretion of ductal bile under basal and hormone-regulated
conditions (1-3, 5-10, 17, 18, 20, 23). For example, secretin
stimulates ductal bile secretion (1, 3, 5-10, 18, 23) by
interaction with specific receptors expressed only by cholangiocytes
(9) through an increase in intracellular levels of cAMP and activation of
Cl We have previously shown in both normal and bile duct-ligated (BDL)
rats that cholangiocytes are morphologically heterogeneous with small
cholangiocytes lining small bile ducts and large cholangiocytes lining
large bile ducts (1, 3, 8, 10). We have also shown, using distinct
subpopulations of cholangiocytes and intrahepatic bile duct units
(IBDU) of different sizes, that secretin-regulated ductal secretion is
present in large (>15 µm in diam) but not small (<15 µm in
diam) IBDU (1, 3, 8, 10).
Cholangiocytes are the target cells in a number of experimental models
of ductal hyperplasia (1, 3, 5, 7, 9, 18, 23). Cholangiocyte
proliferation after BDL is closely associated with an increase in DNA
synthesis, numbers of intrahepatic bile ducts, and ductal secretory
activity (1, 3-5, 7, 9, 18). In the BDL rat model, cholangiocyte
proliferation and increased ductal bile secretion occur in large
cholangiocytes or large IBDU but are absent in small cholangiocytes or
small IBDU (1, 10).
It is well known that administration of a single dose of
CCl4 to rats causes acute necrosis
of hepatocytes in zone 3 of the hepatic lobule (15, 26), resulting in
complete regeneration of hepatocytes after 7 days (26). However, recent
studies (33) have shown that in addition to necrosis a substantial
number of hepatocytes may undergo apoptosis in response to acute
CCl4 treatment. CCl4 hepatoxicity depends on the
dehalogenation of CCl4 catalyzed by cytochrome P-4502E1 in the liver
cell endoplasmic reticulum (15, 29). Treatment with
CCl4 in vivo activates oxygen by the P-4502E1 catalyzed reaction via an
NADPH-dependent mechanism (15, 29). Subsequent dissociation of
superoxide radicals from the
P-4502E1-substrate complex generates
free radicals that react with microsomal membranes to induce lipid
peroxidation that leads to cell membrane damage (15, 29). The
cytochrome P-4502E1 is an enzyme
endowed to epithelial cells originating from the embryonic mid gut
because it has been localized in the rat in pancreas (25) and both
duodenal and jejunal villous cells (34).
No information exists with regard to the effect of
CCl4 on proliferative and
secretory processes of different segments of the intrahepatic biliary
epithelium. Inasmuch as the loss and/or damage of large interlobular
ducts by degenerative or inflammatory processes is thought to be a
major factor in the pathogenesis of human liver diseases (e.g., primary
biliary cirrhosis and primary sclerosing cholangitis) (7), we sought to
develop an animal model of selective bile duct damage that is limited
to large hormone-responsive bile ducts. Rats with ductal hyperplasia
induced by BDL for 1 wk were used in these studies inasmuch as, in
contrast to normal rats, secretin-induced bicarbonate-rich choleresis
can also be measured in vivo (5, 18). Furthermore, with an increase in the number of bile ducts after BDL, a reduction in cholangiocyte proliferative capacity due to injury can be measured more easily. We
found that a single dose of CCl4
in 1-wk BDL rats induces a transient cholangiocyte loss only in large
ducts by cholangiocyte apoptosis, and this was associated with a
reduction of proliferative and secretory processes in large
cholangiocytes. In contrast, small cholangiocytes were resistant to
apoptosis, proliferate in response to
CCl4, and transiently acquire
phenotypes of large cholangiocytes.
Animal Model
ABSTRACT
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES
INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES
/HCO
3
exchanger and Cl
channel
opening (5, 7-8, 10, 17, 18), which induces bicarbonate-rich
choleresis in vivo (5, 18).
MATERIALS AND METHODS
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES
Materials
Reagents were purchased from Sigma Chemical (St. Louis, MO) unless otherwise indicated. Porcine secretin was purchased from Peninsula (Belmont, CA). The substrate forCCl4-Induced Liver Damage Assessed by Transaminase Serum Level Determination and Albumin Gene Expression
In 1-wk BDL (control) rats and 1-wk BDL rats treated with CCl4 or mineral oil, the serum levels of aspartate aminotransferase (AST) and alanine aminotransferase (ALT; associated with hepatic damage) were measured by commercially available kits (Sigma). Parallel to other studies (26), to validate our model of CCl4-induced hepatic damage, we measured steady-state levels of albumin mRNA in total liver RNA samples obtained from 1-wk BDL rats and 1-wk BDL rats treated with CCl4 or mineral oil. Total RNA was isolated from liver tissues by the single-step method of Chomczynski and Sacchi (14). Our molecular analysis for albumin mRNA was performed with total RNA (20 µg) from total liver tissues using the RPA II kit (Ambion, Austin, TX) according to the instructions from the vendor. Antisense riboprobes were transcribed from linearized cDNA templates with T7 or SP6 RNA polymerase using [Purification of Small and Large Cholangiocytes
Subpopulations of small and large cholangiocytes were purified from 1-wk BDL rats and 1-wk BDL rats treated with CCl4 or mineral oil as previously described by us (8, 10). Cell number and viability were assessed by trypan blue exclusion. Mean diameters of the two subpopulations were determined by computerized image analysis (8, 10). Cholangiocyte purity was assessed by histochemistry forAssessment of Apoptosis in 1-Wk BDL Rats and 1-Wk BDL Rats Treated With CCl4 or Mineral Oil
In situ morphological studies and TUNEL analysis. In these studies we used 21 rats. Three of these animals were killed 7 days after BDL (controls). Nine rats received one single dose of CCl4 after 1 wk of BDL and were subsequently killed on day 1 (n = 3), 2 (n = 3), and 7 (n = 3) after CCl4 treatment. The remaining nine rats received one dose of mineral oil (control) and were killed on day 1 (n = 3), 2 (n = 3), and 7 (n =3). After anesthesia with pentobarbital sodium, small pieces of liver tissue were taken from each animal and fixed in 10% Formalin (pH 7.4). Sections (5 µm thick) were cut from two liver blocks for each animal, stained for hematoxylin and eosin, and examined under a light microscope equipped with a reticular frame inserted in the ocular lens. An "In Situ Cell Death Detection Kit" (Boehringer Mannheim, Monza, Italy) was also used in our morphological analysis. The kit was used according to the instructions of the vendor. Briefly, paraffin-embedded sections were immersed in 0.01 M citrate buffers (pH 6.0) and irradiated in a microwave oven (750 W) for 1 min. Background was diminished by preincubating liver sections for 30 min at room temperature with a solution composed of 3% albumin (BSA) and 20% normal bovine serum in PBS. The sections were subsequently incubated for 1 h at 37°C with terminal deoxynucleotidyl transferase and nucleotide mixture with fluorescein-dUTP in reaction buffer. After several washes in PBS, the specimens were resaturated (30 min at room temperature) in 3% BSA and 20% normal bovine serum in PBS and subsequently for 30 min at 37°C with an anti-fluorescein-conjugated antibody (Fab fragment from sheep) conjugated with horseradish peroxidase followed by 3,3'-diaminobenzidine tetrahydrochloride color reaction. In each liver section, the number of apoptotic bodies present in cholangiocytes and the diameter (distance between basement membrane) of the bile duct (in which apoptosis was observed) were evaluated. In each liver section, at least 50 nonoverlapping fields were analyzed. The incidence of apoptosis was expressed as number of apoptotic bodies for 100 cholangiocytes.
DAPI staining. In freshly isolated small and large cholangiocytes from 1-wk BDL rats and 1-wk BDL rats treated with CCl4 or mineral oil, apoptosis was morphologically assessed by nuclear staining with DAPI as described by Que et al. (28). After incubation with DAPI (1 µM for 10 min at 22°C), small and large cholangiocytes were placed on coverslips and transferred to the stage of a Nikon Diaphot microscope equipped with fluorescence and differential interference optics where DAPI fluorescence was visualized with the use of excitation and emission filters of 380 and 460 nm, respectively. Apoptosis was determined by observation of nuclear fragmentation as described by Que et al. (28). In agreement with other studies (28), we used normal rat cholangiocytes treated with beauvericin (10 µM) for 4 h at 37°C as a positive control.
Assessment of Cholangiocyte Proliferation
In situ morphometric analysis of bile duct mass. In coded frozen liver sections (n = 6 for each group) from 1-wk BDL rats and 1-wk BDL rats treated with CCl4 or mineral oil, morphometric analysis of small and large ducts was performed by point count analysis (37) by determining the number of small (<15 µm in diam) and large (>15 µm in diam) bile ducts stained for CK-19, a specific marker for cholangiocytes in rat liver (6, 7). Immunohistochemistry for CK-19 was performed as previously described (23). After staining for CK-19, liver sections were counterstained with hematoxylin and examined in a coded fashion with a Zeiss microscope. Point counting analysis (37) has also been applied by us to measure the number of intrahepatic bile ducts in normal and proliferating liver (23). The duct diameter was estimated from the distance between basement membranes. The data were expressed for each duct as the mean of two diameters taken perpendicular to each other. As previously shown in normal rats (13), there is a close association between bile duct diameter and the number of cholangiocytes.
In vitro molecular analysis. The genetic expression of H3 histone, a specific marker of DNA synthesis (2), was assessed in lysate obtained from tissues and/or organs (~100 mg) and small and large cholangiocytes (3.0 × 106 cells) using the lysate ribonuclease protection assay kit (Direct Protect, Ambion) (18, 23) according to the instructions supplied by the vendor. We used, for each cell sample, 45 µl of lysate containing 4.5 × 105 pure cholangiocyte subpopulations. We used the following 32P-labeled antisense riboprobes: a 204-bp riboprobe encoding the H3 histone gene was transcribed from linearized pGEM4Z-H3 histone cDNA (a gift from Dr. S. Gupta, Albert Einstein Hospital, Bronx, NY) and a 316-bp GAPDH mRNA probe, the housekeeping gene (2, 8-10, 18). Rat spleen and yeast transfer RNAs were the positive and negative controls for H3 histone, respectively; and rat kidney and yeast transfer RNAs were the positive and negative controls for GAPDH, respectively.
Assessment of Ductal Secretory Activity
Secretion receptor gene expression. In small and large cholangiocytes purified from 1-wk BDL rats and 1-wk BDL rats treated with CCl4 or mineral oil, secretin receptor (SR) gene expression was assessed by the lysate ribonuclease protection assay [Direct Prot, Ambion (see above) (18, 23)]. A 318-bp riboprobe encoding the message for SR was transcribed from pGEM4Z-SR (a gift from N. F. LaRusso, Mayo Clinic, Rochester, MN) and a 316-bp GAPDH mRNA probe, the housekeeping gene (2, 8-10, 18).
Assessment of intracellular cAMP levels.
Basal and secretin-induced intracellular cAMP synthesis of small and
large cholangiocytes from 1-wk BDL rats and 1-wk BDL rats treated with
CCl4 or mineral oil were
determined as previously described (1-3, 8, 10, 18, 20, 23). After
isolation, pure preparations of small and large cholangiocytes were
incubated for 1 h at 37°C to restore surface proteins damaged by
treatment with proteolytic enzymes (20). The two subpopulations (1 × 105 cells) were stimulated
with secretin (107 M) in
the presence of 0.2% BSA or 0.2% BSA (control) for 5 min at 22°C
(1-3, 8, 10, 18, 20, 23). After ethanol extraction, cAMP levels
were measured by RIA using a commercially available kit (Amersham).
Studies of in vivo biliary physiology.
After anesthesia with pentobarbital sodium, rats were surgically
prepared for bile collection as previously described by us (5). When
steady-state bile flow was achieved, secretin
(107 M) was infused for 30 min followed by a final infusion of Krebs-Henseleit bicarbonate
solution (KRH) for 60 min. Bile was collected at 10-min intervals, placed in preweighed tubes, and immediately stored at
70°C before determining bicarbonate concentration.
Bicarbonate concentration (measured as total
CO2) in bile from BDL and
CCl4-treated BDL rats was
determined by a Natelson microgasometer apparatus (Scientific
Industries, Bohemia, NY).
Immunohistochemical Analysis of Cytochrome P-4502E1.
Liver tissue obtained from BDL rats was snap frozen and sectioned at 7 µm using a cryostat. Frozen liver sections were placed on polylysine-coated slides and allowed to air dry. Liver sections were fixed in methanol for 10 min atWestern Blot Analysis of Cytochrome P-4502E1
Western blot analysis of cytochrome P-4502E1 was performed in microsomes purified from rat liver (positive control, Chemicon), normal rat hepatocytes (positive control, 1 × 107), or small and large cholangiocytes (1 × 107 each) obtained from 1-wk BDL rats and 1-wk BDL rats treated with a single dose of CCl4 or mineral oil. Microsomes were prepared from hepatocytes or small and large cholangiocytes as previously described (21). Briefly, cell preparations (1 × 107 cells) were resuspended in ice-cold 250 mM sucrose, 100 mM Tris · HCl, 1 mM EDTA, pH 7.2, containing 0.5% Triton X-100, and 8% (vol/vol) protease inhibitors (Complete, Boehringer Mannheim, Mannheim, Germany) and sonicated on ice (30-s bursts) to lyse the cells. The cell lysate was successively centrifuged at 800 g for 10 min, at 13,500 g for 20 min, and at 105,000 g for 60 min at 4°C. The microsomal pellet was suspended in 100 mM sodium phosphate, 10 mM MgCl2, and 20% glycerol, pH 7.4, and immediately processed for Western blot analysis. The total protein concentration of hepatocytes and small and large cholangiocytes was determined by the protein assay from Bio-Rad Laboratories (Hercules, CA). Equal amounts of protein from microsomes purified from normal rat hepatocytes or small and large cholangiocytes were resolved by SDS-10% PAGE and transferred onto a nitrocellulose filter (Bio-Rad). The filter was blocked using a 5% solution of nonfat dry milk in Tris-buffered saline (TBST, composed of 50 mM Tris, 150 mM NaCl, and 0.05% Tween 20). The filter was incubated for 2 h with rotation at room temperature with rabbit anti-human/rat cytochrome P-450 enzyme CYP2E1 polyclonal antibody (Chemicon) diluted 1:1,000 with TBST-5% milk. The filter was then washed five times with TBST and incubated for 1 h with rotation at room temperature with anti-rabbit IgG peroxidase conjugate (enhanced chemiluminescence kit, Amersham Life Science, Little Chalfont, Buckinghamshire, England) diluted 1:100,000 with TBST. The filter was washed again five times with TBST, and proteins were visualized using chemiluminescence (Amersham Life Science). The intensity of the bands was determined by scanning video densitometry using the ChemiImager 4000 low-light imaging system (Alpha Innotech).Statistical Analysis
All data are expressed as means ± SE. The differences between groups were analyzed by Student's t-test when two groups were analyzed or ANOVA if more than two groups were analyzed. ![]() |
RESULTS |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
Characterization of CCl4-Induced Hepatoxicity in BDL Rats
The effects of acute CCl4 or mineral oil treatment on body weight, wet liver weight, and wet liver-to-body weight ratio in BDL rats are shown in Table 1. The effects of CCl4 or mineral oil treatment on transaminase serum levels are shown in Table 2. Consistent with the concept that acute CCl4 treatment induces damage of liver cells, following CCl4 treatment there was a marked increase in the serum levels of AST and ALT compared with 1-wk BDL rats and 1-wk BDL rats treated with mineral oil (Table 2). The increased serum enzyme levels (observed on days 1 and 2 after CCl4 treatment) returned to BDL control values on day 7 after CCl4 treatment (Table 2). As further evidence for hepatocellular damage, we found that the levels of albumin mRNA markedly decreased on both days 1 (~5.6-fold, P < 0.05 vs. control values) and 2 (~3.0-fold, P < 0.05 vs. control values) after CCl4 treatment before returning to values similar to that of 1-wk BDL rats on day 7 (Fig. 1). No significant changes in albumin gene expression were found in total RNA samples from 1-wk BDL rats treated with mineral oil compared with 1-wk BDL rats (Fig. 1). Densitometric analysis of albumin mRNA was normalized to GAPDH gene expression (Fig. 1, right).
|
|
|
Purification of Small and Large Cholangiocytes
By counterflow elutriation we isolated two distinct and pure (byIn Situ Quantitative Evaluation of Apoptosis in Small and Large Intrahepatic Bile Ducts
Liver morphology. The livers of 1-wk BDL rats and 1-wk BDL rats treated with a single dose of mineral oil showed marked proliferation of bile ducts with a pattern similar to that of previous studies (5). In agreement with previous studies (15, 26), 1 day after CCl4 treatment we observed necrosis in the parenchyma, scarce inflammatory infiltrate, and fatty acid changes of the surviving hepatocytes. Proliferating bile ductules (<15 µm in diam) were often seen in close proximity to or surrounded by necrotic hepatocytes and showed vacuolization of the cytoplasm without evidence of advanced necrosis. Two days after CCl4 treatment necrosis was usually restricted to zone 3, whereas liver morphology 7 days after CCl4 treatment was similar to 1-wk BDL rats or 1-wk BDL rats treated with mineral oil.
Quantitative evaluation of apoptosis.
Morphological analysis of the intrahepatic biliary epithelium in 1-wk
BDL rats (control) and 1-wk BDL rats on day
1 after CCl4
treatment showed a few apoptotic bodies, which appeared as small
acidophilic globules often containing nuclear material localized between two adjacent cholangiocytes, engulfed within their cytoplasm, or released into the biliary lumen without an associated inflammatory response. The number of apoptotic bodies/100 cholangiocytes observed in
large (diam >15 µm) bile ducts significantly increased in BDL rats
2 days after CCl4 treatment (Fig.
2) with respect to BDL rats 2 days after
oil treatment (0.46 ± 0.03 vs. 0.20 ± 0.05 apoptotic bodies/100
cholangiocytes in CCl4-treated and
oil-treated rats, respectively, P < 0.001). Seven days after CCl4
treatment the number of apoptotic bodies was similar to that of BDL
rats 7 days after oil treatment (0.19 ± 0.09 vs. 0.16 ± 0.04, P > 0.05) in CCl4-treated and oil-treated rats,
respectively. The increase in the number of apoptotic bodies observed
in large bile ducts 2 days after
CCl4 treatment compared with BDL
oil-treated rats (P < 0.001) was
also confirmed by TUNEL analysis. The number of apoptotic bodies, when
present, for each bile duct ranged between 1 and 4. Apoptosis was never
observed in small (diam <15 µm) bile ducts from 1-wk BDL rats and
1-wk BDL rats treated with CCl4 or mineral oil. Acute CCl4 treatment
did not result in morphological evidence of necrosis in cholangiocytes.
We did not detect a significant increase of hepatocyte apoptosis with
respect to controls after acute
CCl4 treatment.
|
Quantitative measurement of apoptosis by DAPI staining in small and
large cholangiocytes.
Nuclear fragmentation, determined by nuclear staining by DAPI (28), was
employed as criteria for assessing apoptosis in pure preparations of
small and large cholangiocytes from 1-wk BDL rats and 1-wk BDL rats
treated with CCl4 or mineral oil.
In small and large cholangiocytes from BDL (control) rat livers, we did
not detect apoptosis (Fig.
3A,
a and
d); cells showed homogeneous distribution of chromatin with intact nuclei. In contrast, large cholangiocytes from CCl4-treated
BDL rats (Fig. 3A,
e) displayed morphological
characteristics of apoptosis evidenced by chromatin condensation and
nuclear fragmentation (28) on day 2 after CCl4 treatment. No apoptosis
was detected in small cholangiocytes on day
2 after acute CCl4
treatment (Fig. 3A,
b). Quantitative assessment of
percentage of cholangiocytes with nuclear fragmentation showed that
CCl4 induced apoptosis in large
(but not small) cholangiocytes on day
1 and 2 after acute
CCl4 treatment before returning to BDL control levels on day 7 (Fig.
3B). No apoptosis was seen in small
or large cholangiocytes from 1-wk BDL rats treated with mineral oil
(Fig. 3B). Normal cholangiocytes
treated with 10 µM beauvericin (the positive control, results not
shown) displayed the same morphological features of apoptosis that we
observed in cholangiocytes from
CCl4-treated BDL rats.
|
Measurement of Cholangiocyte Proliferative Capacity
In situ morphometric analysis.
By in situ morphometry, we measured the number of small and large
intrahepatic bile ducts estimated from the percentage of tissue section
occupied by bile ducts smaller and greater than 15 µm in diameter,
respectively (Fig. 4). These studies showed that the percent volume of large bile ducts in liver markedly decreased
on day 2 after
CCl4-treatment compared with 1-wk
BDL rats but returned to values similar to that of 1-wk BDL control rats on day 7 after
CCl4 treatment (Fig. 4). In
contrast to the CCl4-induced loss
of large bile ducts, we found an increase in percent volume in the
liver of small (<15 µm in diam) bile ducts on day
2 after CCl4
treatment compared with 1-wk BDL liver. The percent volume of small
bile ducts in liver returned to values comparable to that of 1-wk BDL
control rat liver on day 7 after CCl4 treatment (Fig. 4). No
significant changes in the number of large ducts were observed in BDL
rats on days 1 and
2 after acute oil treatment (Fig. 4).
We found a significant (P < 0.05) increase in the number of large (but not small) ducts on
day 7 after oil administration
compared with 1-wk BDL control rats (Fig. 4), which is consistent with
our previous observations that BDL stimulates proliferative capacity in
large but not small cholangiocytes (4).
|
In vitro assessment of cholangiocyte proliferative capacity.
The transcript for the H3 histone
gene was absent in small cholangiocytes from 1-wk BDL rats (Fig.
5). In contrast,
H3 histone gene expression
(normalized to the genetic expression of GAPDH) markedly increased in
small cholangiocytes on both days 1 (~70% increase) and 2 (~90%
increase) before declining to undetectable levels on
day 7 after
CCl4 treatment (Fig. 5).
In contrast, in large cholangiocytes
H3 histone gene expression
decreased 10% on day 1 and 50% on
day 2 before returning to BDL control
values 7 days after CCl4 treatment
(Fig. 5). The expression of the housekeeping gene GAPDH was similar
among small and large cholangiocytes from BDL,
CCl4-, and oil-treated 1-wk BDL
rats (Fig. 5). No changes in H3
histone gene expression were observed in large cholangiocytes on
days 1,
2, and
7 after acute oil treatment compared
with large cholangiocytes from 1-wk BDL control rats (Fig.
5). The message for H3 histone
was absent in small cholangiocytes on days
1, 2, and
7 after control oil treatment (Fig.
5). Thus our morphological (Fig. 4) and molecular (Fig. 5) studies of
proliferating bile ducts in BDL rats show that
CCl4 causes transient decreases in DNA synthesis in large cholangiocytes and loss of large ducts. In
contrast, CCl4 induces an increase
in DNA synthesis in small cholangiocytes and an increased number of
small ducts in BDL rats.
|
Measurement of Ductal Secretory Activity
SR gene expression.
In large cholangiocytes SR gene expression decreased 50% on
day 1 and was absent on
day 2 after
CCl4 treatment (Fig.
6). In large cholangiocytes, the genetic
expression of SR mRNA returned to 1-wk BDL control values on
day 7 after
CCl4 treatment (Fig. 6). SR mRNA
was absent in small cholangiocytes from BDL rats but there was de novo
expression of SR on day 1,
which increased further on day 2 before returning to undetectable values on
day 7 after acute
CCl4 treatment (Fig. 6). No
changes in SR gene expression were seen in large cholangiocytes on
days 1,
2, and
7 after control oil treatment compared
with large cholangiocytes from 1-wk BDL control rats (Fig. 6). The
message for SR was absent in small cholangiocytes on
days 1,
2, and
7 following acute oil treatment (Fig.
6).
|
Intracellular cAMP levels.
Ductal secretion was estimated in purified cholangiocytes from
measurement of secretin-stimulated cAMP synthesis. In large cholangiocytes from 1-wk BDL rats, secretin markedly increased intracellular cAMP levels (Fig. 7). On
day 2 after
CCl4 treatment, secretin-induced
cAMP levels markedly decreased in large cholangiocytes before returning
to values similar to 1-wk BDL rats 7 days after acute
CCl4 treatment (Fig. 7). No
increase in secretin-induced cAMP synthesis was observed in small
cholangiocytes from 1-wk BDL rats (Fig. 7). But on
days 1 and
2 after acute
CCl4 treatment secretin-stimulated
cAMP synthesis appears in small cholangiocytes (Fig. 7). The de novo
secretin-induced cAMP synthesis in small cholangiocytes disappeared on
day 7 after
CCl4 treatment (Fig. 7).
The control oil treatment did not affect basal or secretin-stimulated cAMP levels in large cholangiocytes or induce secretin-stimulated cAMP
synthesis in small cholangiocytes (Fig. 7).
|
Studies of biliary physiology.
Secretin significantly (P < 0.05) increased both bile flow and bicarbonate secretion in
1-wk BDL rats (control) and 1-wk BDL rats on days
1, 2, and
7 after acute mineral oil treatment
(Table 3). In
CCl4-treated rats, the choleretic
effect of secretin on days 1 and
2 after
CCl4 treatment was markedly
reduced (Table 3). Similarly, secretin-induced biliary bicarbonate
secretion was reduced on both days 1 and 2 after
CCl4 treatment. Both
secretin-induced bile flow and bicarbonate secretion returned to
control BDL values on day 7 after
CCl4 treatment (Table 3),
indicating restoration of ductal secretory activity. After
CCl4 administration, the transient loss of ductal secretion in vivo (i.e., secretin-induced bile flow and
bicarbonate secretion) occurred at the same time period as the loss of
SR gene expression and secretin-stimulated cAMP synthesis in large
purified cholangiocytes (Figs. 6 and 7 and Table 3).
|
Immunohistochemical and Immunoblotting Analysis of P-4502E1
Immunohistochemistry of frozen liver sections from BDL rats showed positive staining for cytochrome P-4502E1 in bile ducts (Fig. 8). A positive reaction was also observed in hepatocytes. Immunoblotting analysis shows that a signal (migrating at 52 kDa) for cytochrome P-4502E1 was expressed in large but not small cholangiocytes purified from BDL rats (Fig. 9). We found on both days 1 and 2 after CCl4 treatment a marked decrease in the expression of cytochrome P-4502E1 in large cholangiocytes compared with large cholangiocytes from 1-wk BDL control rats (Fig. 9). Concomitant with restoration of functions of large damaged bile ducts, the expression of cytochrome P-4502E1 returned to values similar to that of 1-wk BDL control rats (Fig. 9). Mineral oil treatment did not alter the expression of cytochrome P-4502E1 in large cholangiocytes compared with large cholangiocytes from 1-wk BDL control rats (Fig. 9). Cytochrome P-4502E1 protein expression remained absent in small cholangiocytes purified from CCl4- or oil-treated BDL rats (Fig. 9).
|
|
![]() |
DISCUSSION |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
The major findings of these studies relate to the development and morphological, biochemical, molecular, and functional characterization of an animal model of selective bile duct damage that is restricted to large hormone-responsive ducts. In 1-wk BDL rats subsequently treated by gavage with a single dose of CCl4, we found that 2 days after CCl4 administration, the number of large (>15 µm in diam) bile ducts decreased. Consistent with the finding of bile duct loss limited to large ducts, 2 days after acute CCl4 treatment, apoptosis was detected in large ducts and cholangiocytes, respectively. DNA synthesis transiently decreased in large cholangiocytes. Inasmuch as large isolated cholangiocytes are localized in large bile ducts in BDL rats (1), the loss of proliferative capacity in large isolated cholangiocytes corresponds with the reduction of numbers of large ducts in 2-day CCl4-treated rats. Finally, consistent with CCl4-induced bile duct damage limited to large hormone-responsive ducts, there was ablation of secretin-induced bicarbonate-rich choleresis in CCl4-treated BDL rats and a marked decrease in SR gene expression and secretin-induced cAMP levels in large purified cholangiocytes. The inhibitory effects of CCl4 on large cholangiocyte growth and secretion were transient, with restoration to BDL control values by day 7. We have previously shown (1, 3, 8, 10) that small cholangiocytes and small bile ducts are morphologically and functionally different from the remainder of the biliary tree due to their lack of secretin receptor and absence of proliferative response to BDL. The present study shows that small cholangiocytes in small ducts are also different in their pathophysiological response to CCl4. First, we did not observe apoptosis in small purified cholangiocytes or small ducts in situ. Second, small cholangiocytes had increased DNA synthesis leading to an increased number of small bile ducts. Finally, small cholangiocytes developed de novo SR gene expression and secretin-stimulated cAMP synthesis. These studies further extend our previous observations (1, 3, 4, 8, 10) that not only are cholangiocytes in different-sized ducts physiologically heterogeneous with regard to proliferative and secretory processes, they are also fundamentally different in their responses to pathological injury. Moreover, the studies represent the first evidence for a physiological role of small cholangiocytes that do not respond to secretin (1, 3, 8, 10) and are mitotically inactive after BDL (1) but de novo develop secretory activity and begin to proliferate after acute CCl4 treatment.
To explain the different sensitivities of small and large cholangiocytes to CCl4 toxicity, we demonstrated that cytochrome P-4502E1, the enzyme that initiates CCl4 hepatoxicity (15, 19), is present in large but not small cholangiocytes. The loss of duct function and cholangiocyte loss by apoptosis limited to large bile ducts may be initiated by cytochrome P-4502E1 metabolism of CCl4 in large cholangiocytes. Small bile ducts are resistant to damage and to induction of apoptosis due to absence of CCl4 metabolism by cytochrome P-4502E1 in small cholangiocytes. The different sensitivity of small and large cholangiocytes to CCl4 based on cytochrome P-4502E1 presence is completely analogous to the CCl4-induced centrilobular hepatocellular necrosis due to higher cytochrome P-4502E1 in centrilobular region (12). In support of our findings, other investigators have shown cytochrome P-4502E1 in large but not small human bile ducts (22), which would indicate that toxins like CCl4 have the potential to directly injure the human biliary tree as well. Other previous studies (38) have shown selective toxicity of a number of chemicals (e.g., organic arsenicals and chlorpropamide) toward large intrahepatic ducts. These studies, however, failed to quantitate bile duct function in response to injury and did not elucidate the mechanisms of duct injury as we accomplished in the present studies.
Employing a number of end points of cholangiocyte proliferation and secretion, we demonstrated that acute CCl4 treatment induces transient damage to large hormone-responsive ducts in BDL rats, which is associated with a decrease in proliferative capacity and secretory processes of large cholangiocytes. The greatest injury to large ducts occurs on day 2 after acute CCl4 treatment, concomitant with the peak of hepatocellular injury (increased transaminases and decreased albumin gene expression). At the peak of hepatoxicity on day 2, cytochrome P-4502E1 expression in large cholangiocytes diminishes. This loss of P-4502E1 at the time of maximum toxicity may provide a protective effect from further CCl4-induced damage. Like the transient effects of CCl4 on hepatocyte function (15, 26), large cholangiocytes and large bile ducts respond with proliferation and complete restoration of the numbers of intrahepatic bile ducts, duct secretory function, and cytochrome P-4502E1 expression on day 7 following acute CCl4 treatment.
Over the course of CCl4-induced hepatoxicity, we evaluated the morphological evidence of apoptosis in both in situ liver sections and purified cholangiocytes. We found apoptosis to be low in 1-wk BDL control rats, which indicates that BDL alone does not induce apoptosis in cholangiocytes. On days 1 and 2 after acute CCl4 treatment, we detected by in situ morphometry apoptosis in large but not small bile ducts. Similarly, on days 1 and 2 after CCl4 treatment, we found (by DAPI staining) apoptosis in large but not small isolated cholangiocytes with nuclear fragmentation that was identical to our control beauvericin-induced cholangiocyte apoptosis (28). Although our observations of apoptosis in cholangiocytes contrast with a number of studies showing hepatocyte necrosis after acute CCl4 treatment, it does agree with other models of bile duct loss such as primary biliary cirrhosis or vanishing bile duct syndrome where cholangiocytes are lost by apoptosis (27). Other studies have shown that in addition to necrosis hepatocytes undergo apoptosis in response to acute CCl4 treatment (33).
In addition to showing damage of large bile ducts, the studies demonstrated that small cholangiocytes not only are resistant to CCl4 injury without morphological features of apoptosis but also de novo proliferate beginning 1 day after acute CCl4 treatment. Proliferation of large cholangiocytes after acute CCl4 treatment is delayed, and we postulate that this delay in proliferation is due to selective apoptosis in large cholangiocytes. In support of this concept, apoptosis has been shown to either delay or prevent proliferative response of other cell types (16). The explanation for the resistance of small cholangiocytes to apoptosis may be due to the absence of cytochrome P-4502E1 in small cholangiocytes or perhaps to their more undifferentiated nature (32, 35), similar to the chemical toxin resistance of other precursor cells (30).
Although SR gene expression and secretin-induced cAMP levels are increased in small cholangiocytes on day 2 after CCl4 treatment, secretin did not increase bile flow in vivo. On day 2 after CCl4 treatment small proliferating bile ducts are either inadequate in number or not fully differentiated at this early time point and thus not able to generate bile in response to secretin in vivo. Moreover, the presence and the increase of both SR gene expression and secretin-induced cAMP synthesis are not necessarily associated with enhanced secretin-stimulated ductal bile flow (5, 18, 23). For example, in normal rat liver, SR is present on cholangiocytes (9) and secretin increases cAMP levels in purified cholangiocytes (8, 10, 18, 23). However, secretin still does not increase bile flow.
Proliferation of small bile ducts (which occurs on days 1 and 2 after acute CCl4 treatment) contrasts with the BDL model, where only large cholangiocytes proliferate (4), but is similar to our findings in partial hepatectomized rats where we found that small cholangiocytes transiently proliferate to replace the lost ducts (24). Both CCl4 hepatoxicity and partial hepatectomy represent models of transient bile duct loss. It is reasonable to speculate that small cholangiocytes proliferate in these models to restore the biliary tree. As an extension of this hypothesis there is the potential of migration of small proliferating cholangiocytes into larger ducts, which has been proposed to occur in normal rat liver at a very slow rate (11). Further studies are needed, using labeled cholangiocytes to determine if migration of small cholangiocytes into larger ducts occurs in animal models of bile duct loss, including CCl4-induced toxicity. Although it has been previously shown (35) that undifferentiated cells in terminal bile ducts may rarely be activated by transdifferentiation to hepatocytes, in BDL rats acutely treated with CCl4 we did observe glucose 6-phosphatase expression in our cholangiocyte subpopulations. Our observation that small cholangiocytes transiently proliferate only when large cholangiocyte function is impaired also suggests the possibility that large cholangiocytes may signal small cholangiocytes to begin to proliferate. Further studies, however, are necessary to examine the potential of signaling (cross talk) between cholangiocyte subpopulations of different sizes.
We believe that our novel studies have an important pathophysiological relevance. This is the first study that morphologically and functionally characterizes a model of selective apoptosis restricted to the large hormonally responsive segments of the intrahepatic biliary tree. Although an in vitro model of cholangiocyte apoptosis has been previously described (28), our studies are the first to develop and pathophysiologically characterize an in vivo model of cholangiocyte apoptosis. Our studies showing cholangiocyte apoptosis in a bile duct injury animal model are consistent with previous findings that cholangiocytes are lost by apoptosis in human liver disease (e.g., primary biliary cirrhosis and primary sclerosing cholangitis) characterized by bile duct loss (27). Further studies of CCl4-induced cholangiocyte apoptosis may disclose potential mechanisms for apoptosis in human liver disease. Understanding the mechanisms by which specific cholangiocyte subpopulations (originating from different portions of the biliary tree) differentially respond to pathological perturbations (e.g., BDL) or hepatotoxic agents (e.g., CCl4) may increase our knowledge of the selective involvement of certain sized ducts in human cholestatic liver diseases (e.g., primary biliary cirrhosis and primary sclerosing cholangitis).
![]() |
ACKNOWLEDGEMENTS |
---|
We thank Bryan Moss for outstanding photographic and art work and Laura Ugili for excellent technical assistance.
![]() |
FOOTNOTES |
---|
This work was supported by a grant award to both G. Alpini and G. D. LeSage from Scott & White Hospital and Texas A&M University and by a Veterans Affairs Merit Award to G. Alpini and partially by a Grant Award from Scott & White Hospital to S. S. Glaser.
Portions of this study have been presented at the American Association for the Studies of Liver Diseases and have been published in abstract form (Hepatology 24: 509, 1996).
The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. §1734 solely to indicate this fact.
Address for reprint requests and other correspondence: G. Alpini, Departments of Internal Medicine and Medical Physiology, the Texas A & M University System Health Science Center, College of Medicine and Central Texas Veterans Health Care System, 1901 South 1st St., Bldg. 147, Temple, TX 76504 (E-mail: falpini{at}bellnet.tamu.edu).
Received 27 May 1998; accepted in final form 4 February 1999.
![]() |
REFERENCES |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
1.
Alpini, G.,
S. Glaser,
W. Robertson,
J. Phinizy,
J. Lasater,
R. Rodgers,
and
G. LeSage.
Large but not small intrahepatic bile ducts (IBDU) from bile duct ligated (BDL) rats proliferate and are involved in secretin-induced ductal bile secretion (Abstract).
Hepatology
24:
A84,
1996.
2.
Alpini, G.,
S. Glaser,
W. Robertson,
J. L. Phinizy,
R. Rodgers,
A. Caligiuri,
and
G. LeSage.
Bile acids stimulate proliferative and secretory events in large but not small cholangiocytes.
Am. J. Physiol.
273 (Gastrointest. Liver Physiol. 36):
G518-G529,
1997
3.
Alpini, G.,
S. Glaser,
W. Robertson,
R. Rodgers,
J. L. Phinizy,
J. Lasater,
and
G. D. LeSage.
Large but not small intrahepatic bile duct units are involved in secretin-regulated ductal bile secretion in normal rat liver.
Am. J. Physiol.
272 (Gastrointest. Liver Physiol. 35):
G1064-G1074,
1997
4.
Alpini, G.,
S. Glaser,
Y. Ueno,
L. Pham,
P. Podila,
A. Caligiuri,
G. LeSage,
and
N. F. LaRusso.
Heterogeneity of the proliferative capacity of rat cholangiocytes following bile duct ligation.
Am. J. Physiol.
274 (Gastrointest. Liver Physiol. 37):
G767-G775,
1998
5.
Alpini, G.,
R. Lenzi,
L. Sarkozi,
and
N. Tavoloni.
Biliary physiology in rats with bile ductular cell hyperplasia. Evidence for a secretory function of proliferated bile ductules.
J. Clin. Invest.
81:
569-578,
1988[Medline].
6.
Alpini, G.,
R. Lenzi,
W.-R. Zhai,
P. A. Slott,
M. H. Liu,
L. Sarkozi,
and
N. Tavoloni.
Bile secretory function of intrahepatic biliary epithelium in the rat.
Am. J. Physiol.
257 (Gastrointest. Liver Physiol. 20):
G124-G133,
1989
7.
Alpini, G.,
J. O. Phillips,
and
N. F. LaRusso.
The biology of the biliary epithelia.
In: The Liver; Biology & Pathobiology (3rd ed.), edited by I. Arias,
J. L. Boyer,
N. Fausto,
W. Jakoby,
D. Schachter,
and D. A. Shafritz. New York: Raven, 1994, p. 623-653.
8.
Alpini, G.,
S. K. Roberts,
S. M. Kuntz,
Y. Ueno,
S. Gubba,
P. Podila,
G. LeSage,
and
N. F. LaRusso.
Morphologic, molecular and functional heterogeneity of cholangiocytes from normal rat liver.
Gastroenterology
110:
1637-1643,
1996.
9.
Alpini, G.,
C. Ulrich II,
J. Phillips,
L. Pham,
L. Miller,
and
N. LaRusso.
Upregulation of secretin receptor gene expression in rat cholangiocytes after bile duct ligation.
Am. J. Physiol.
266 (Gastrointest. Liver Physiol. 29):
G922-G928,
1994
10.
Alpini, G.,
C. Ulrich,
S. K. Roberts,
J. O. Phillips,
Y. Ueno,
P. Podila,
O. Colegio,
G. LeSage,
L. J. Miller,
and
N. F. LaRusso.
Molecular and functional heterogeneity of cholangiocytes from rat liver after bile duct ligation.
Am. J. Physiol.
272 (Gastrointest. Liver Physiol. 35):
G289-G297,
1997
11.
Arber, N.,
and
G. Zajicek.
Streaming liver. VI: Streaming intra-hepatic bile ducts.
Liver
10:
205-208,
1990[Medline].
12.
Azri, S.,
H. P. Mata,
L. L. Reid,
A. J. Gandolfi,
and
K. Brendel.
Further examination of the selective toxicity of CCl4 in rat liver slices.
Toxicol. Appl. Pharmacol.
112:
81-86,
1992[Medline].
13.
Benedetti, A.,
C. Bassotti,
K. Rapino,
L. Marucci,
and
A. M. Jezequel.
A morphometric study of the epithelium lining the rat intrahepatic biliary tree.
J. Hepatol.
24:
335-342,
1996[Medline].
14.
Chomczynski, P.,
and
N. Sacchi.
Single-step method of RNA isolation by acid guanidium thiocyanate-phenolchloroform extraction.
Anal. Biochem.
162:
156-159,
1987[Medline].
15.
Clawson, G. A.
Mechanisms of carbon tetrachloride hepatoxicity.
Path. Immunopathol. Res.
8:
104-112,
1989.
16.
Darby, I. A.,
T. Bisucci,
T. D. Hewitson,
and
D. G. MacLellan.
Apoptosis is increased in a model of diabetes-impaired wound healing in genetically diabetic mice.
Int. J. Biochem. Cell Biol.
29:
191-200,
1997[Medline].
17.
Fitz, J. G.,
S. Basavappa,
J. McGill,
O. Melhus,
and
J. A. Cohn.
Regulation of membrane chloride currents in rat bile duct epithelial cells.
J. Clin. Invest.
91:
319-328,
1993[Medline].
18.
Glaser, S.,
R. Rodgers,
J. L. Phinizy,
W. Robertson,
J. Lasater,
A. Caligiuri,
Z. Tretjak,
G. LeSage,
and
G. Alpini.
Gastrin inhibits secretin-induced ductal secretion by interaction with specific receptors on rat cholangiocytes.
Am. J. Physiol.
273 (Gastrointest. Liver Physiol. 36):
G1061-G1070,
1997
19.
Handler, J. A.,
and
R. S. Goldstein.
Xenobiotic metabolism and toxic responses of intrahepatic biliary epithelium.
In: Biliary and Pancreatic Ductal Epithelia. Pathobiology and Pathophysiology, edited by A. E. Sirica,
and D. S. Longnecker. New York: Marcel Dekker, 1996, p. 181-199.
20.
Kato, A.,
G. J. Gores,
and
N. F. LaRusso.
Secretin stimulates exocytosis in isolated bile duct epithelial cells by a cyclic AMP-mediated mechanism.
J. Biol. Chem.
267:
15523-15529,
1992
21.
Kremers, P.,
P. Beaune,
T. Cresteil,
J. de Graeve,
S. Columelli,
J. P. Leroux,
and
J. E. Gielen.
Cytochrome P-450 monooxygenase activities in human and rat liver microsomes.
J. Biochem. (Tokyo)
118:
599-606,
1981.
22.
Lakehal, F.,
D. Wendum,
P. Beaune,
F. Ballet,
R. Poupon,
and
C. Housset.
Heterogeneous expression of drug-metabolizing enzymes in human biliary epithelial cells (Abstract).
Hepatology
26:
A1075,
1997.
23.
LeSage, G.,
S. Glaser,
S. Gubba,
W. E. Robertson,
J. L. Phinizy,
J. Lasater,
R. Rodgers,
and
G. Alpini.
Regrowth of the rat biliary tree after 70% partial hepatectomy is coupled to increased secretin-induced ductal bile secretion.
Gastroenterology
111:
1633-1644,
1996[Medline].
24.
LeSage, G.,
S. Glaser,
W. Robertson,
J. Phinizy,
R. Rodgers,
and
G. Alpini.
Partial hepatectomy induces proliferative and secretory events in small cholangiocytes (Abstract).
Gastroenterology
110:
A1250,
1996.
25.
Norton, I. D.,
M. V. Apte,
P. S. Haber,
G. W. McCaughan,
R. C. Pirola,
and
J. S. Wilson.
Cytochrome P4502E1 is present in rat pancreas and is induced by chronic ethanol administration.
Gut
42:
426-430,
1998
26.
Panduro, A.,
F. Shalaby,
F. R. Weiner,
L. Biempica,
M. Zern,
and
D. A. Shafritz.
Transcriptional switch from albumin to -fetoprotein and changes in transcription of other genes during carbon tetrachloride induced liver regeneration.
Biochemistry
25:
1414-1420,
1986[Medline].
27.
Que, F. G.,
and
G. J. Gores.
Cell death by apoptosis: basic concepts and disease relevance for the gastroenterologist.
Gastroenterology
110:
1238-1243,
1996[Medline].
28.
Que, F. G.,
G. J. Gores,
and
N. F. LaRusso.
Development and initial application of an in vitro model of apoptosis in rodent cholangiocytes.
Am. J. Physiol.
272 (Gastrointest. Liver Physiol. 35):
G106-G115,
1997
29.
Recknagel, R. O.,
E. A. Glende, Jr.,
J. A. Dolak,
and
R. L. Waller.
Mechanisms of carbon tetrachloride toxicity.
Pharmacol. Ther.
43:
139-154,
1989[Medline].
30.
Reese, J. S.,
O. N. Koc,
K. Lee,
J. E. Schupp,
and
S. L. Gerson.
Selection for G156A O6-methylguanine DNA methyltransferase gene-transduced hematopoietic progenitors and protection from lethality in mice treated with O6-benzylguanine and 1,3-bis (2-chloroethyl)-1-nitrosourea.
Cancer Res.
57:
5093-5099,
1997[Abstract].
31.
Rutemberg, A. M.,
H. Kim,
J. W. Fishbein,
J. S. Hanker,
H. L. Wasserkrug,
and
A. M. Seligman.
Histochemical and ultrastructural demonstration of -glutamyl transpeptidase activity.
J. Histochem. Cytochem.
17:
517-526,
1969[Medline].
32.
Schrenk, D.,
I. Eisenmann-Tappe,
R. Gebhardt,
D. Mayer,
M. El Moielhi,
E. Rohrdanz,
P. Munzel,
and
K. W. Bock.
Drug metabolizing enzyme activities in rat liver epithelial cell lines, hepatocytes and bile duct cells.
Biochem. Pharmacol.
41:
1751-1757,
1991[Medline].
33.
Shi, J.,
K. Aisaki,
Y. Ikawa,
and
K. Wake.
Evidence of hepatocyte apoptosis in rat liver after the administration of carbon tetrachloride.
Am. J. Pathol.
153:
515-525,
1998
34.
Shimizu, M.,
J. M. Lasker,
M. Tsutsumi,
and
C. S. Lieber.
Immunohistochemical localization of ethanol-inducible P450IIE1 in the rat alimentary tract.
Gastroenterology
99:
1044-1053,
1990[Medline].
35.
Sirica, A. E.,
and
T. W. Williams.
Appearance of ductular hepatocytes in rat liver after bile duct ligation and subsequent zone 3 necrosis by carbon tetrachloride.
Am. J. Pathol.
140:
129-136,
1992[Abstract].
36.
Teutsch, H. F.
Improved method for the histochemical demonstration of glucose-6-phosphatase activity. A methodological study.
Histochemistry
57:
107-117,
1978[Medline].
37.
Weibel, E. R.,
and
D. Gomez.
A principle for counting tissue structure on random sections.
Appl. Physiol.
17:
3443-3448,
1962.
38.
Zimmerman, H. J.,
and
J. H. Lewis.
Drug-induced cholestasis.
Med. Tekh.
2:
112-160,
1987.